Unicycive Therapeutics (UNCY)

• Market cap: $71.4M
• 1 day: 1.25%
• 5 days: -5.83%
• 1 month: -0.98%
• 3 months: -41.19%
• 6 months: -30.46%
• Year to date: -48.99%
• 1 year: 6.88%
• 5 years: -93.09%
• 10 years: -93.09%
• Sector: Healthcare
• Industry: Biotechnology

About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Employees: 22

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

34.92% more ownership

Funds ownership: 5.77% [Q1] → 40.69% (+34.92%) [Q2]

29% less capital invested

Capital invested by funds: $34.5M [Q1] → $24.6M (-$9.83M) [Q2]

34% less funds holding

Funds holding: 29 [Q1] → 19 (-10) [Q2]

71% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 14

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $21
• Avg. target: $21
• High target: $21

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Benchmark Bruce D. Jackson

$21

Speculative Buy Maintained

15 Sep 2025